The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg
butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
BioKier Inc. Juvenile Diabetes Research Foundation